Stable session for GSK stock as £1,950 support draws focus

Traders Union
All News
Financial News
GSK slides 0.75% today to GBX 2,000.97

Highlights

GSK broadened its collaboration with Novavax to co-develop advanced vaccines for influenza and RSV, enhancing its pipeline prospects.
The company is experiencing continued growth in its vaccines business and expects revenue and net income to rise in upcoming quarters.
GBX trades below key short- and medium-term moving averages amid oversold technical conditions, with a near-term range of GBX 1,950 to GBX 2,060 and high odds of a reversal if resistance at GBX 2,054 is breached.

Vaccine partnership and portfolio momentum support positive earnings view

GSK expanded its partnership with Novavax to co-develop next-generation vaccine platforms targeting influenza and respiratory syncytial virus (RSV). The company reported momentum in its vaccines portfolio and operational improvements in R&D. GSK is expected to post increases in both revenue and net income in upcoming quarters, though price action has remained under broader selling pressure.

Bearish momentum endures as oversold signals meet key resistance

On the technical side, GSK trades beneath the MA-20 (GBX 2,108.10) and MA-50 (GBX 2,102.96), with the MA-200 (GBX 1,778.37) providing longer-term support. Immediate resistance lies at the Ichimoku Kijun level of GBX 2,054.14. Daily momentum signals remain negative, as the MACD and ADX show neutral to bearish readings while RSI stands at 38.40. Additional indicators, such as the CCI, Stoch RSI, and BBP, point to oversold conditions and pronounced seller dominance, with the AO reinforcing a prevailing downside bias.

Potential rebound hinges on reclaiming technical resistance in volatile range

Over the next five trading days, GSK is likely to stabilize within a typical volatility band of GBX 1,950 to GBX 2,060. With most weekly indicators showing bullish signals, the probability of an upward move is high, provided the price can reclaim and hold above the immediate resistance at GBX 2,054. A downside scenario could materialize if GSK breaks below GBX 1,950, exposing the asset to further pullbacks.

Viktoras Karapetjanc, expert at Traders Union, sees GSK's fundamentals improving with renewed vaccine partnerships and better R&D execution. He notes that despite technical headwinds and prevailing negative momentum, long-term support remains intact. The analyst expects that if the price reclaims GBX 2,054.14, upside could accelerate in the near term. Karapetjanc is constructive given bullish weekly signals. "If GSK holds above GBX 2,054, I see strong potential for a rebound this week."

Earlier, analysts noted that GSK shares were under persistent short- and medium-term selling pressure despite support from longer-term technical strength and ongoing buybacks. With the company advancing its vaccine portfolio and most weekly indicators now turning bullish, a sustained move above the immediate resistance at GBX 2,054 could signal the start of a medium-term rebound.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.